Research
Hormonal
SGLT2 inhibitors reduce the risk of heart failure hospitalization and cardiovascular death in patients with heart failure with reduced ejection fraction (HFrEF), regardless of diabetes status.
If you have heart failure, especially with reduced ejection fraction, ask your doctor about SGLT2 inhibitors like empagliflozin or dapagliflozin. These drugs help your heart pump better and reduce hospitalizations, even if you don't have diabetes.
StrongSupportsVERY_HIGH confidence
Empagliflozin Outcome Trial in Patients with Chronic Heart Failure and a Reduced Ejection Fraction (EMPEROR-Reduced) trial found that in patients with class II, III, or IV heart failure with reduced ejection fraction (HFrEF) of <40%... those who randomly assigned to receive 10 mg of empagliflozin daily... had a significantly lower incidence of cardiovascular death or hospitalization for worsening heart failure compared to placebo (19.4% vs 24.7%) regardless of the presence of diabetes.
Why this rating
Supported by EMPEROR-Reduced and DAPA-HF trials.
Source
Pharmacologic Therapies for Type 2 Diabetes
Bryan Kuo et al. · NEJM Evidence · 2025
DOI 10.1056/evidra2400265
narrative_review
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- GLP-1 receptor agonists (GLP-1 RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) reduce major adverse cardiovascular events (MACE) and heart failure hospitalizations in patients with type 2 diabetes, independent of glycemic control.Strong
- Tirzepatide, a dual GLP-1/GIP receptor agonist, provides greater HbA1c reduction and weight loss compared to semaglutide 1 mg in patients with Type 2 Diabetes.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →